Reply
We thank Drs. O'Rourke and Nichols for their enthusiastic interest and insightful comments regarding our report on the potential benefits of sodium nitroprusside (SNP) in the setting of advanced decompensated heart failure (ADHF) (1) . We are in complete agreement regarding the many factors that influence left ventricular (LV) afterload, including the concept that aortic impedance can be a more integrated measure of LV afterload. We would like to emphasize that throughout the article there had not been any assertion or assumptions that measuring systemic vascular resistance in ADHF better reflects LV afterload compared with aortic input impedance. It is also not the intention of our retrospective case series to compare the effectiveness or safety of administration of SNP guided by a reduction in vascular resistance or aortic input impedance. In fact, titration of SNP doses was based on achieving a measured target mean arterial blood pressure of 65 to 70 mm Hg and not on achieving a normal derived systemic vascular resistance. Nevertheless, even with this relatively crude method in the absence of specialized equipment, the substantial improvement in cardiac output secondary to sodium nitroprusside therapy was associated with more favorable (rather than adverse) long-term outcomes. Although invasive measurements were used in our protocol, it is not the intention of these data to always imply the need for invasive monitoring, but solely to understand the hemodynamic contributors and subsequent changes induced by sodium nitroprusside during the treatment of ADHF. As with interpreting the clinical utility of any biomarker, there is an important distinction between identifying individual patients who may have the appropriate hemodynamic profiles to benefit from a specific intervention versus using specific indexes of LV afterload as targets of therapeutic interventions. We agree that much promise exists regarding the use of noninvasive hemodynamic monitoring. Nevertheless, in much the same way that pharmacotherapeutics require rigorous placebo-controlled testing in the specific population with the specific treatment goals to be certain of benefit, diagnostic tools intended to guide therapy may require the same validation, especially regarding use in the acutely ill heart failure population.
The letter by Drs. O'Rourke and Nichols appropriately addresses alternative modalities for assessing aortic impedance (a component of left ventricular afterload), and importantly expands on our earlier discussion regarding the measurement of peripheral resistance and incorporating the use of those measurements in the treatment of advanced decompensated heart failure. The paper by Mullens et al. (1) and accompanying editorial comment (2) do not exclude other monitoring modalities, but rather address what is practically available and importantly highlight the potential benefit of vasodilator therapy and emphasize the need to consider decompensated heart failure as a disease entity driven not only by congestion but also by altered ventricular loading conditions. There is reasonable hesitancy to the full embrace of the use of nitroprusside if indeed that use requires invasive hemodynamic monitoring. Not only does invasive hemodynamic monitoring seem to be necessary, but also skill in caring for such catheters in an intensive care unit setting and skill in interpreting the data are required. Titrating the vasodilator dose to hemodynamics is yet another unique skill set required to use nitroprusside successfully in this clinical scenario.
A noninvasive strategy that addresses one of several components of left ventricular afterload, be it aortic impedance, brachial/radial arterial resistance, or transthoracic bioimpedance, would be preferable. The dilemma is that use of those noninvasive strategies in an intensive care unit setting for patients with advanced decompensated heart failure cannot be assumed to be accurate and reproducible without undergoing prospective testing. The test should be proven to be reliable, reproducible, and accurate when compared with a known conventional hemodynamic parameter. Utility of certain modalities in the realm of hypertension is not sufficient to verify utility in the setting of heart failure, especially when aortic flow characteristics and tissue factors related to impedance may be strikingly different. As well, if the noninvasive strategy introduces a new metric, the ability to titrate therapy according to that metric should be proven.
It is agreed that any evidence-based beneficial measurement of peripheral resistance that obviates the need for right heart catheterization would be preferable as greater use of vasodilator therapy seems warranted in the setting of advanced decompensated heart failure. 
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